Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/K19BazV
No comments:
Post a Comment